Baillie Gifford & Co
SGMO

Baillie Gifford & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Baillie Gifford & Co’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,510
Closed -$4.42K – 419
2023
Q1 		$4.42K Hold
2,510
– – ﹤0.01% 422
2022
Q4 		$7.88K Hold
2,510
– – ﹤0.01% 428
2022
Q3 		$12K Hold
2,510
– – ﹤0.01% 396
2022
Q2 		$10K Buy
+2,510
New +$10.9K ﹤0.01% 413

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co's SGMO Position: Q2 2023 in Review

Baillie Gifford & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2023, closing a stake of 2,510 shares — an estimated $4.42K sold.

Baillie Gifford & Co first reported a position in SGMO in Q2 2022 and held it in 4 quarters. The position peaked at $12K in Q3 2022. 152 funds tracked by Wall St. Rank hold SGMO as of Q2 2023.

  • Baillie Gifford & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 2,510 SANGAMO THERAPEUTICS INC shares in Q2 2023, an estimated $4.42K.
  • Baillie Gifford & Co first reported a position in SANGAMO THERAPEUTICS INC in Q2 2022 and held it in 4 quarters.
  • Baillie Gifford & Co's SANGAMO THERAPEUTICS INC position peaked at $12K in Q3 2022.
  • 152 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.